Lv1
39 积分 2024-09-29 加入
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
9天前
已完结
Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists
15天前
已完结
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study
2个月前
已完结
Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations
2个月前
已完结
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression
3个月前
已完结
Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
3个月前
已完结
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression
3个月前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
3个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
3个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
3个月前
已完结
皖公网安备34019202002308
